

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT3623787

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
INVADO PHARMACEUTICALS LLC	02/27/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
<b>Street Address:</b>	2150 ST. ELZEAR BLVD. WEST
<b>City:</b>	LAVAL, QUÉBEC
<b>State/Country:</b>	CANADA
<b>Postal Code:</b>	H7L 4A8
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	14945865
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(585)232-2152
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	585-231-1286
<b>Email:</b>	jthomas@hselaw.com
<b>Correspondent Name:</b>	JOHN E. THOMAS, ESQ.
<b>Address Line 1:</b>	1600 BAUSCH & LOMB PLACE
<b>Address Line 4:</b>	ROCHESTER, NEW YORK 14604-2711
<b>ATTORNEY DOCKET NUMBER:</b>	99336.000190
<b>NAME OF SUBMITTER:</b>	JOHN E. THOMAS
<b>SIGNATURE:</b>	/John E Thomas/
<b>DATE SIGNED:</b>	11/19/2015
<b>Total Attachments: 5</b>	
source=99336-190_62093026_Assignment-Invado-to-Valeant#page1.tif	
source=99336-190_62093026_Assignment-Invado-to-Valeant#page2.tif	
source=99336-190_62093026_Assignment-Invado-to-Valeant#page3.tif	
source=99336-190_62093026_Assignment-Invado-to-Valeant#page4.tif	
source=99336-190_62093026_Assignment-Invado-to-Valeant#page5.tif	

## PATENT ASSIGNMENT AGREEMENT

THIS PATENT ASSIGNMENT AGREEMENT (this "Patent Assignment") dated as of March 6, 2015, is made by and between Invado Pharmaceuticals LLC, a New York limited liability company ("Seller") and Valeant Pharmaceuticals International, Inc., a British Columbia corporation ("Purchaser"). Seller and Purchaser are collectively referred to herein as the "Parties" and individually as a "Party."

### RECITALS

WHEREAS, the Sellers and the Purchaser have entered into that certain Asset Purchase Agreement, dated as of February 27, 2015 (the "Asset Purchase Agreement"), pursuant to which, among other things, the Sellers have agreed to sell, convey, assign, transfer and deliver to the Purchaser all rights, titles and interests of the Sellers in and to the Assigned Patents (as defined below), and the Purchaser has agreed to acquire and accept all rights, titles and interests of the Sellers in and to the Assigned Patents from the Sellers.

NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1. Assigned Patents. "Assigned Patents" means the patents and patent applications listed on Schedule 1 attached hereto, together with any continuations, continuations, continuations-in-part, divisionals, reissues, re-examinations, substitutions and extensions thereof.

2. Assignment. Each of the Sellers does hereby sell, convey, transfer, assign and deliver to the Purchaser all right, title and interest of the Sellers in and to the Assigned Patents for the Purchaser's own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Sellers if this Patent Assignment and sale had not been made, together with all income, royalties, damages or payments due or payable as of the Effective Date or thereafter, including, without limitation, the right to sue and recover damages for past, present and future infringement of any of the Assigned Patents.

3. Recordation. Each of the Sellers hereby requests and authorizes the Commissioner of Patents and Trademarks, and any other applicable governmental entity, to record the Purchaser as the owner of the Assigned Patents, as assignee of the entire right, title and interest in and to the same. The Purchaser shall have the right to record this Patent Assignment with all applicable governmental entities so as to perfect its ownership of the Assigned Patents.

4. Counterparts. This Patent Assignment may be executed in counterparts, and by the parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement by facsimile transmission or by e-mail of a .pdf attachment shall be effective as delivery of a manually executed counterpart of this Agreement

5. Further Assurances. Each of the parties hereto agrees to execute and deliver such documents, and to take such actions, as may be reasonably requested by the other party to give effect to this Patent Assignment and to vest, perfect, confirm, record or otherwise reflect the parties' rights as set forth herein.

6. Governing Law; Submission of Jurisdiction; Waiver of Jury Trial.

(a) This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to any conflicts of law principles thereof to the extent such principles would permit or require the application of the laws of another jurisdiction.

(b) The Parties consent to the exclusive jurisdiction of the Federal and State courts located in Delaware with respect to all disputes related to this Agreement. Each of the Parties (i) consents to the jurisdiction of each such court in any such suit, action or proceeding, (ii) waives any objection that it may have to the laying of venue in any such suit, action or proceeding in any such court and (iii) agrees that service of any court paper may be made in such manner as may be provided under applicable Laws or court rules governing service of process. **THE PARTIES HEREBY IRREVOCABLY WAIVE, AND AGREE TO CAUSE THEIR RESPECTIVE AFFILIATES TO WAIVE, THE RIGHT TO TRIAL BY JURY IN ANY SUCH ACTION PERMITTED HEREUNDER.**

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the Parties have executed or caused this Patent Assignment to be executed as of the date first written above.

INVADO PHARMACEUTICALS LLC

By: Edward D. Kobus

Name: Edward D. Kobus

Title: President / Founder

VALEANT PHARMACEUTICALS  
INTERNATIONAL, INC.

By: \_\_\_\_\_

Name:

Title:

[Signature Page to Patent Assignment Agreement]

IN WITNESS WHEREOF, the Parties have executed or caused this Patent Assignment to be executed as of the date first written above.

INVADO PHARMACEUTICALS LLC

By: \_\_\_\_\_

Name:

Title:

VALEANT PHARMACEUTICALS  
INTERNATIONAL, INC.



By: \_\_\_\_\_

Name: Laizer Kornwasser

Title: Executive Vice President

[Signature Page to Patent Assignment Agreement]

PATENT  
REEL: 037089 FRAME: 0444

**Schedule 1**

**Assigned Patents**

United States Patent Application Number 62/093026 filed December 17, 2014 for  
FORMULATIONS OF CALCIUM PHOSPHATE FOR ORAL INFLAMMATION